Burning Rock Biotech (NASDAQ:BNR) Director Acquires $999,990.00 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han purchased 111,110 shares of the stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average cost of $9.00 per share, for a total transaction of $999,990.00. Following the transaction, the director owned 18,018,546 shares in the company, valued at approximately $162,166,914. The trade was a 0.62% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han acquired 24,900 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $8.00 per share, with a total value of $199,200.00.
• On Wednesday, June 24th, Yusheng Han acquired 250,000 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $8.00 per share, with a total value of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han acquired 5,990 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $7.50 per share, with a total value of $44,925.00.
• On Monday, June 22nd, Yusheng Han bought 104,650 shares of Burning Rock Biotech stock. The shares were purchased at an average cost of $7.45 per share, for a total transaction of $779,642.50.
• On Friday, June 12th, Yusheng Han bought 210,000 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han bought 24,760 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Stock Performance

Burning Rock Biotech stock opened at $9.82 on Friday. The firm has a 50 day simple moving average of $12.35 and a 200-day simple moving average of $19.96. The stock has a market cap of $103.31 million, a price-to-earnings ratio of -11.98 and a beta of 1.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.05 and a quick ratio of 2.81. Burning Rock Biotech Limited Sponsored ADR has a 1-year low of $3.23 and a 1-year high of $41.72.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($2.29) by $2.09. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%. The firm had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million.

Analysts Set New Price Targets

A number of research firms have commented on BNR. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Burning Rock Biotech currently has an average rating of “Sell”.

Institutional Investors Weigh In On Burning Rock Biotech

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new position in shares of Burning Rock Biotech in the 4th quarter worth approximately $220,000. Prospera Financial Services Inc boosted its position in shares of Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock worth $628,000 after purchasing an additional 6,430 shares during the period. Renaissance Technologies LLC increased its holdings in Burning Rock Biotech by 13.8% in the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after purchasing an additional 4,290 shares during the last quarter. Finally, Crcm LP increased its holdings in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock valued at $1,917,000 after purchasing an additional 26,809 shares during the last quarter. 30.03% of the stock is owned by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.